|
|
|
|
EASL - The International Liver Congress 2014
49th Annual Meeting of the European Association for the Study of the Liver
London, United Kingdom April 9-13 |
|
|
- SPONTANEOUS CLEARANCE RATES INCREASE WITH HCV REINFECTION EPISODE IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM) INDEPENDENT OF HCV SUBTYPE - (06/17/15)
 
- Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day Monotherapy in Patients With and Without Compensated Cirrhosis With Hepatitis C Virus (HCV) Genotype 1 Infection - (05/04/15)
 
- New DAA Phase 3 Studies for genotype 1 at EASL - in both Treatment-naives, treatment-experienced; simultaneous publications - (04/21/14)
 
- The Impact of Fibrosis on the Risk of Long-Term Morbidity & Mortality in Chronic Hepatitis C Patients Treated in the US Veterans Health Administration Health Care System - advanced HCV disease correlated with risk for hospitalization/events/death - (08/13/14)
 
- Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization - low treatment rates & high resource utilization rate too with IFN-based therapies boceprevir or telaprevir or INF-based Double Therapy In A Large Health Maintenance Organization - (08/13/14)
 
- Comorbidities Associated with Not Being Treated for HCV - (08/13/14)
 
-
HCV in India at EASL: IDUs, Burden, Limited Access - (05/09/14)
 
- Effect of alisporivir (ALV) on the pharmacokinetics (PK), safety, and tolerability of methadone in healthy subjects and opioid-dependent patients on stable methadone maintenance therapy (MMT) - (05/05/14)
 
- Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM.......Eleven persons were re-infected......The cumulative incidence was 33% within 2 years - (05/02/14)
 
- Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010 "appears to level off in recent years" in Amsterdam Clinic - (05/02/14)
 
- Stabilizing Incidence of Hepatitis C Virus Infection among Men who have Sex with Men in Amsterdam - (05/02/14)
 
-
ADDING PEGINTERFERON TO ENTECAVIR INCREASES RESPONSE RATES IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS: WEEK 96 RESULTS OF A GLOBAL MULTICENTER RANDOMISED TRIAL (ARES STUDY) - (05/01/14)
 
- Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study: The NEED study - (05/01/14)
 
- Response-Guided Peginterferon Alfa-2a (PegIFN Alfa-2a) Therapy in Patients with HBeAg-Positive Chronic Hepatitis B (CHB) - (05/01/14)
 
- High Burden of Fibrosis and Metabolic Cofactors in a Cohort of Predominantly Genotype 3-Infected Injection Drug Users in Southern India - (05/01/14)
 
- Limited Access to HCV Testing and Treatment among Injection Drug Users across India - (04/30/14)
 
- Hepatocellular Carcinoma (HCC) incidence in Chronic Hepatitis C patients (CHC) according to Sustained Virologic Response (SVR) and baseline characteristics - (04/30/14)
 
- EFFECTIVENESS OF TENOFOVIR FOR CHRONIC HEPATITIS B IN FIELD PRACTICE - (04/30/14)
 
- Nucleos(t)ide Analogue (NA) Therapy for Persons in the Immunotolerant Phase of CHB Is Associated With Significant Declines in HBeAg and HBsAg Levels - (04/30/14)
 
- THE EFFICACY OF ENTECAVIR IN BOTH NAĻVE AND LAMIVUDINE EXPERIENCED WITHOUT RESISTANCE CHRONIC HEPATITIS B PATIENTS - (04/30/14)
 
- ENTECAVIR AND TENOFOVIR HAVE A COMPARABLE EFFICACY IN TREATMENT OF NUCLEOS(T)IDE ANALOGUE NAĻVE PATIENTS WITH CHRONIC HEPATITIS B: A REAL LIFE EXPERIENCE - (04/30/14)
 
- RANDOMIZED TRIAL OF TENOFOVIR MONOTHERAPY VERSUS TENOFOVIR PLUS ENTECAVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B PATIENTS WITH GENOTYPIC RESISTANCE MUTATIONS TO ADEFOVIR - (04/30/14)
 
- LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY - (04/30/14)
 
- LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP) - (04/30/14)
 
- High Burden of HCV & HIV/HCV Coinfection among Injection Drug Users in India: Need for Integration of HIV & HCV Services - (04/28/14)
 
- Determinants of Variability in ISG15 Gene Expression in Patients With Chronic Hepatitis B (CHB) Infection During Treatment With Oral TLR-7 Agonist GS-9620 - (04/28/14)
 
- Ledipasvir and Sofosbuvir Combination Improves Patient-Reported Outcomes During Treatment of Chronic Hepatitis C: The Result from ION-1 Clinical Trial - (04/24/14)
 
- Health-Related Quality of Life (HRQL) and Patient-Reported Outcomes (PROs) Assessment in Chronic Hepatitis C (CH-C) Treated with Sofosbuvir (SOF) and Ribavirin (RBV): The VALENCE Study (Gt2/3)....extending treatment to 24 weeks - (04/24/14)
 
- Independent Predictors of Patient-Reported Outcomes (PROs) and Quality of Life (QOL) in Chronic Hepatitis C Patients Receiving Interferon (IFN) -Free versus IFN-Containing Regimens with Sofosbuvir (SOF) - (04/24/14)
 
- Estimating Health Status Using EQ-5D for Chronic Hepatitis C (CH-C) Patients Treated with Sofosbuvir Containing Regimens - (04/24/14)
 
- Improvement of Central Fatigue is Associated with Sustained Virologic Response (SVR) Following Sofosbuvir-Containing Regimens - (04/24/14)
 
- INDEPENDENT PREDICTORS OF PATIENT-REPORTED OUTCOMES (PROS) AND QUALITY OF LIFE (QOL) IN CHRONIC HEPATITIS C PATIENTS RECEIVING INTERFERON (IFN)-FREE VERSUS IFN-CONTAINING REGIMENS WITH SOFOSBUVIR (SOF) - (04/23/14)
 
- Quality of Life Improved by SVR, Ifn-Free Therapy Improves Better - (04/23/14)
 
- IMPACT OF NEW DAA-CONTAINING REGIMENS ON HCV TRANSMISSION AMONG INJECTING DRUG USERS (IDUS): A MODEL-BASED ANALYSIS (ANRS 12376)...."Test & Treat", Eliminating HCV - (04/22/14)
 
- New DAA Phase 3 Studies for genotype 1 at EASL - in both Treatment-naives, treatment-experienced; simultaneous publications - (04/21/14)
 
- Peginterferon Lambda for the Treatment of Chronic Hepatitis B (CHB): A Phase 2b Comparison With Peginterferon Alfa in Patients With HBeAg-Positive Disease (LIRA-B) - (04/21/14)
 
- REDUCED INCIDENCE OF HEPATOCELLULAR CARCINOMA IN HIV/HBV-COINFECTED PATIENTS RECEIVING TENOFOVIR - (04/21/14)
 
- SVR IS ASSOCIATED WITH NO RISK REDUCTION OF HCC DEVELOPMENT IN PATIENTS WITH HCV-RELATED CIRRHOSIS. A PROSPECTIVE, UP-TO 23 YEARS, COHORT FOLLOW-UP STUDY - (04/21/14)
 
- Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 study. - (04/21/14)
 
- Resistance Analysis of HCV Genotype 1 Patients Treated With Sofosbuvir in Combination With Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669: The ELECTRON Study - (04/21/14)
 
- Long-term Follow-up of Patients Treated With Sofosbuvir in the Phase 3 Studies FISSION, POSITRON, FUSION, and NEUTRINO - (04/21/14)
 
- Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the VALENCE Trial - (04/21/14)
 
- Integrated Safety Analysis of Sofosbuvir-Based HCV Treatment Regimens From Phase 3 Studies - (04/21/14)
 
- Modeling Predicts Clinically Meaningful SVR Rates in Genotype 1 Treatment-Experienced Patients Based on Results in Genotype 1 Treatment-Naïve Patients Treated With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks - (04/21/14)
 
- Ledipasvir/Sofosbuvir Retreating Prior Failures Phase 3 - (04/21/14)
 
- Abbvie 3-D in Cirrhosis Phase 3/Liver Transplants Phase 2 - (04/21/14)
 
- Low Persistence of Resistance-Associated Variants After 3 Days of Monotherapy With NS5B NNI Site II Inhibitor GS-9669 in Genotype 1 HCV Patients - (04/21/14)
 
- Efficacy and Safety of MK-5172 Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection: Final Results of the C-SPIRIT Study - (04/21/14)
 
- Safety and Efficacy of MK-5172 Plus Peginterferon Alfa-2b and Ribavirin (PR) in Cirrhotic and Noncirrhotic Treatment-Naive Patients With Hepatitis C Virus (HCV) Genotype (G)1 Infection - (04/21/14)
 
-
Comparative Resistance Analysis Between Cirrhotic and Non-cirrhotic Treatment Experienced Patients Who Failed Treatment With a Combination of Vaniprevir (MK-7009) and Pegylated Interferon and Ribavirin (P/R) - (04/21/14)
 
- Futility Testing at Treatment Week 8 in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection Receiving Boceprevir: A Post Hoc Analysis - (04/21/14)
 
- Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in European patients who relapsed after previous interferon-based therapy: the PROMISE trial - (04/17/14)
 
- Virology analyses of simeprevir in Phase 2b and 3 studies - (04/17/14)
 
- Deep sequencing analyses of minority baseline polymorphisms and persistence of emerging mutations in HCV genotype 1-infected patients treated with simeprevir - (04/17/14)
 
- Comorbid Conditions Associated With Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C In A Large U.S. Health Maintenance Organization - (04/17/14)
 
- RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION - (04/16/14)
 
- PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-naïve HCV Genotype 1b-Infected Adults With or Without Ribavirin - (04/16/14)
 
- An Interferon- and Ribavirin-Free 12-Week Regimen of Once-Daily VX-135 and Daclatasvir in Treatment-Naïve Patients With Genotype 1 HCV Infection - (04/16/14)
 
- Sofosbuvir Plus Ribavirin, an Interferon-Free Regimen, in the Treatment of Treatment-Naïve and -Experienced Patients With Chronic Genotype 4 HCV Infection - (04/16/14)
 
- Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter Study - (04/16/14)
 
- Sofosbuvir and Daclatasvir for Recurrent Hepatitis C After Liver Transplantation: Potent Antiviral Activity But Lack of Clinical Benefit if Treatment is Given Too Late - (04/16/14)
 
- Pharmacokinetic (PK) Drug-Drug Interaction between Samatasvir (IDX719), a Pan-Genotypic NS5A Inhibitor, and Simeprevir in Healthy Volunteers and HCV-Infected Subjects - (04/16/14)
 
- A Phase II Study of Samatasvir (IDX719) in Combination with Simeprevir and Ribavirin in Treatment-Naïve HCV-Infected Subjects with Genotypes 1b and 4 (HELIX-1 Study) - (04/16/14)
 
- Favorable Preclinical Profile of IDX21437, a Novel Uridine Nucleotide Prodrug, for Use in a Direct-Acting Antiviral (DAA) Regimen for HCV - (04/16/14)
 
- EASL Coverage: 6 phase 3 studies; Simeprevir+Sofosbuvir Update; HIV Coinfection: 2 studies reported - (04/15/14)
 
- 2 HIV/HCV Coinfection Studies at EASL - (04/15/14)
 
- Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients - (04/15/14)
 
- EASL Recommendations (Guidelines) on Treatment of Hepatitis C 2014 - (04/15/14)
 
- Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis - (04/14/14)
 
- Efficacy and Safety of Daclatasvir in Combination With Asunaprevir in Cirrhotic and Non-Cirrhotic Patients With HCV Genotype 1b: Results of the HALLMARK-DUAL Study - (04/14/14)
 
- SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172 / MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHy STUDY - (04/14/14)
 
- Successful Retreatment of HCV Genotype-1 Infected Patients Who Failed Prior Therapy with Peg-interferon + Ribavirin Plus 1 or 2 Other Direct-Acting Antiviral Agents with Sofosbuvir - (04/14/14)
 
- Sofosbuvir Compassionate Use Program for Patients with Severe Recurrent Hepatitis C Including Fibrosing Cholestatic Hepatitis Following Liver Transplantation - (04/14/14)
 
- Gilead's Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease - press release - (04/14/14)
 
- Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) - (04/14/14)
 
- Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors - (04/14/14)
 
- Successful Retreatment With Sofosbuvir-containing Regimens for HCV Genotype 2 or 3 Infected Patients who Failed Prior Sofosbuvir Plus Ribavirin Therapy - (04/14/14)
 
- HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN - (04/14/14)
 
- All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study
- (04/14/14)
 
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection - (04/14/14)
 
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection - (04/14/14)
 
- All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study - (04/14/14)
 
- RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/r/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION - (04/14/14)
 
- Safety and Efficacy of Treatment With Interferon-Free, Ribavirin-Free Combination of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Patients With Genotypes 1-6 HCV Infection - (04/14/14)
 
- All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study - (04/14/14)
 
- TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
 
- Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2) - (04/14/14)
 
- All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1b Infection: Phase 3 HALLMARK-DUAL Study Results - (04/14/14)
 
- ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis - Phase 3 TURQUOISE-II - (04/14/14)
 
- Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients, and GT 1 Patients With Prior Sofosbuvir Experience - (04/11/14)
 
-
EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY - (04/11/14)
 
- Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hepatitis C Genotype 1 Infected Patients with cirrhosis or previous null response: the C-WORTHY Study - (04/11/14)
 
-
Effect of Baseline NS5A Polymorphisms on Virologic Response to the All-Oral Combination of Daclatasvir + Sofosbuvir ± Ribavirin in Patients With Chronic HCV Infection - (04/11/14)
 
- Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety - (04/11/14)
 
- Effect of Baseline NS5A Polymorphisms on Virologic Response to the All-Oral Combination of Daclatasvir + Sofosbuvir ± Ribavirin in Patients With Chronic HCV Infection - (04/11/14)
 
- SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 MG AND 50 MG DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS - (04/11/14)
 
- Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection - (04/11/14)
 
- EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY - (04/11/14)
 
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis - (04/11/14)
 
- AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™ - (04/11/14)
 
- Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin (in previously untreated patients with HCV genotype 1 infection and no cirrhosis) - (04/11/14)
 
- SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAïVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
 
- Ledipasvir/Sofosbuvir With and Without Ribavirin for 8 Weeks Compared to Ledipasvir/Sofosbuvir for 12 Weeks in Treatment-Naïve Noncirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 ION-3 Study - (04/11/14)
 
- RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION - (04/11/14)
 
- Dose-dependent Pharmacokinetics for MK-5172 25 mg, 50 mg, and 100 mg Once Daily for 12 Weeks in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients - (04/11/14)
 
-
SOFOSBUVIR/LEDIPASVIR IN RETREATMENT OF HCV GENOTYPE-1 PATIENTS WHO PREVIOUSLY FAILED SOFOSBUVIR/RIBAVIRIN THERAPY - (04/10/14)
 
- Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients - (04/10/14)
 
- USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 INFECTION IN PATIENTS COINFECTED WITH HIV (Interim results) - (04/10/14)
 
-
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin - (04/10/14)
 
- SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
 
- AASLD Preparing Providers for Hepatitis Patients: Online Hepatitis Program for Primary Care Providers - (04/10/14)
 
- WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection - (04/09/14)
 
|
|
|
|
|
|
|
|
|